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Background: Neuroinflammation and biometal dyshomeostasis are key pathological
features of several neurodegenerative diseases, including Alzheimer’s disease (AD).
Inflammation and biometals are linked at the molecular level through regulation of metal
buffering proteins such as the metallothioneins. Even though the molecular connections
between metals and inflammation have been demonstrated, little information exists on
the effect of copper modulation on brain inflammation.
Methods: We demonstrate the immunomodulatory potential of the copper
bis(thiosemicarbazone) complex CuII(atsm) in an neuroinflammatory model in vivo and
describe its anti-inflammatory effects on microglia and astrocytes in vitro.
Results: By using a sophisticated in vivo magnetic resonance imaging (MRI) approach,
we report the efficacy of CuII(atsm) in reducing acute cerebrovascular inflammation
caused by peripheral administration of bacterial lipopolysaccharide (LPS). CuII(atsm)
also induced anti-inflammatory outcomes in primary microglia [significant reductions in
nitric oxide (NO), monocyte chemoattractant protein 1 (MCP-1), and tumor necrosis
factor (TNF)] and astrocytes [significantly reduced NO, MCP-1, and interleukin 6 (IL-6)]
in vitro. These anti-inflammatory actions were associated with increased cellular copper
levels and increased the neuroprotective protein metallothionein-1 (MT1) in microglia
and astrocytes.
Conclusion: The beneficial effects of CuII(atsm) on the neuroimmune system suggest
copper complexes are potential therapeutics for the treatment of neuroinflammatory
conditions.
Keywords: microglia, astrocyte, inflammation, neurodegeneration, copper
Frontiers in Neuroscience | www.frontiersin.org 1 September 2018 | Volume 12 | Article 668
fnins-12-00668 September 20, 2018 Time: 13:52 # 2
Choo et al. CuII(atsm) Attenuates Neuroinflammation
INTRODUCTION
Chronic neuroinflammation, manifested by increased activation
of glial cells and excessive production of pro-inflammatory
mediators, is one of the hallmark pathological features of several
neurodegenerative diseases, including AD, multiple sclerosis,
PD, and ALS. During neurodegeneration, chronic stimulation
results in unresolved inflammation and creates a neurotoxic
environment that exacerbates degeneration in the brain. The view
that the brain is an immune-privileged site has been challenged
by studies demonstrating the presence of bidirectional crosstalk
between the CNS and the immune system (Louveau et al., 2015).
It is now clear that during peripheral immune activation, the
innate immune system signals to the brain, thereby inducing pro-
inflammatory cytokine production and global gene expression
changes in the brain (Thomson et al., 2014), as well as defects
in spatial learning and memory (Jurgens et al., 2012; Eimerbrink
et al., 2015; Elmore et al., 2015). Therapeutic approaches targeted
to the modulation of both central and peripheral inflammation
during neurodegeneration have shown beneficial outcomes in
animal models and in human patients (Heneka et al., 2015;
Venigalla et al., 2016).
Copper is required for many critical neuronal processes and
functions, including differentiation, cell signaling, and synaptic
transmission (D’Ambrosi and Rossi, 2015; Maureira et al., 2015;
Hatori et al., 2016). Alterations to biometal homeostasis are
implicated in several neurodegenerative diseases. For example, in
PD, copper levels are diminished in the affected substantia nigra
brain region (Genoud et al., 2017). In AD, X-ray fluorescence
(XRF) analyses have shown that amyloid plaques are enriched
for copper and zinc (Miller et al., 2006), yet several studies have
demonstrated that many important regions such as the neocortex
are in fact copper deficient in AD patient brains (Schrag et al.,
2011; Rembach et al., 2013; Graham et al., 2014). Therefore,
both the sequestration of copper in plaques and loss of copper-
dependent functions have been proposed to contribute to AD
pathology. Given the importance of biometal homeostasis on
neuronal function, therapeutic targeting of abnormal biometal
balance has been clinically demonstrated to be a potential
therapeutic approach for neurodegeneration (Faux et al., 2010).
Modulating brain copper homeostasis is beneficial in
animal models of neurodegenerative diseases. Copper
Abbreviations: Aβ, amyloid beta; AD, Alzheimer’s disease; ALS, amyotrophic
lateral sclerosis; BCA, bichinchoninic acid; CNS, central nervous system;
CuII(gtsm), glyoxalbis(N(4)-methyl-3-thiosemicarbazonato)copper(II);
CuII(atsm), diacetylbis(N(4)-methyl-3-thiosemicarbazonato)copper(II); DIV,
days in vitro; DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent
assay; FBS, fetal bovine serum; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; ICP-MS, inductively coupled plasma mass spectrometry;
IFNγ, interferon gamma; IL, interleukin; iNOS, inducible nitric oxide synthase;
LPS, lipopolysaccharide; MCP-1/CCL2, monocyte chemoattractant protein 1;
MPIO-VCAM-1, microparticles of iron conjugated to vascular cell adhesion
molecule 1 antibody; MRI, magnetic resonance imaging; MT1, metallothionein-1;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NO,
nitric oxide; Nrf2, nuclear factor erythroid 2-like 2; PBS, phosphate-buffered
saline; PD, Parkinson’s disease; PDTC, pyrrolidine dithiocarbamate; PFA,
paraformaldehyde; qRT-PCR, quantitative real-time polymerase chain reaction;
RT, room temperature; SSV, standard suspension vehicle; TNFα, tumor necrosis
factor α; XFM, X-ray fluorescence microscope.
bis(thiosemicarbazones) (btscs) are stable, lipophilic neutral
copper(II) complexes that are capable of crossing cell membranes
and the blood–brain barrier (Donnelly et al., 2008; Torres et al.,
2016). Changes to the backbone of the ligand change the CuII/I
reduction potential and lead to changes in the propensity of Cu-
btscs to release Cu(I) inside cells (Donnelly et al., 2012). Metal
delivery and metal redistribution with these complexes reduced
disease-associated cognitive decline and improved learning and
memory in AD model mice (Crouch et al., 2009), preserved
motor function and survival in ALS mice (Soon et al., 2011;
McAllum et al., 2013; Roberts et al., 2014), and improved both
motor and cognitive functions in mouse models of PD (Hung
et al., 2012). The copper bis(thiosemicarbazone) CuII(atsm) is
currently under clinical investigation in ALS and PD patients
(NCT02870634, NCT03136809, and NCT03204929). In addition,
it has been shown that other copper modulating compounds also
improve learning and memory in AD model mice (Malm et al.,
2007; Adlard et al., 2011), while dietary treatment of AD model
mice with copper (Bayer et al., 2003), and crossing AD model
mice with ATP7b mutant mice (Phinney et al., 2003), which
display elevated copper levels, both result in extended lifetime
and reduced production of amyloid beta (Aβ). The ability of
the metal complexes CuII(gtsm) and CuII(atsm) to improve
cognition in AD and motor performance in ALS has been
attributed to reduction of Aβ oligomers and tau phosphorylation
(Crouch et al., 2009), as well as the ability to improve the copper
content of the metallo-protein Cu/Zn superoxide dismutase
(SOD1) (Roberts et al., 2014) and reduce nitrosative damage
(Soon et al., 2011). However, the observed reductions in the
activation status of microglia and astrocytes in ALS and stroke
mice treated with the copper complex CuII(atsm) (Soon et al.,
2011; Roberts et al., 2014; Huuskonen et al., 2017) suggest a
potential anti-inflammatory effect of copper delivery in vivo, that
has not been fully explored.
Inflammation regulates the expression of critical metal ion
transport proteins in the brain (Terwel et al., 2011; Pelizzoni
et al., 2013; Raha et al., 2013; Urrutia et al., 2013; Zhang et al.,
2014; Michaelis et al., 2015), and several inflammatory proteins
and transcription factors are dependent on metal ions for their
activity. Inflammation also regulates metal buffering proteins
such as the metallothioneins (Liu et al., 2014; Zhou et al., 2014;
Luo et al., 2015). Metallothioneins are present in elevated levels in
neurodegenerative diseases including AD and PD (Duguid et al.,
1989; Adlard et al., 1998; Carrasco et al., 2006; Hidalgo et al.,
2006; Michael et al., 2011) influence inflammatory responses in
neurodegenerative diseases (Potter et al., 2007; Chung et al., 2009;
Kim et al., 2012), and their deficiency is reported to enhance
inflammatory cell responses (Potter et al., 2007). Even though
the molecular links between metals and inflammation have been
demonstrated, little information exists on the effect of copper
modulation on brain inflammation.
In this study, we investigated the immunomodulatory
potential of the neuroprotective copper agent CuII(atsm) in a
neuroinflammatory model in vivo and examined the effects of
the copper complex on microglia and astrocytes in vitro. We
demonstrate that CuII(atsm) reduces brain inflammation caused
by peripheral administration of bacterial LPS. We demonstrate
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that CuII(atsm) has cell-specific inflammation-reducing actions
in vitro, and report that its anti-inflammatory actions are
associated with increased expression of Mt1, encoding the
neuroprotective protein metallothionein-1 (MT1). The observed
anti-inflammatory actions could account for some of the
previously observed neurotherapeutic effects of copper delivery.
MATERIALS AND METHODS
Animals
Four-month-old C57BL/6J male mice (n = 5–6/group) were used
in this study. Male mice were used, because previous studies
suggest that brain copper levels depend more on strain and age
rather than sex (Maynard et al., 2002). Animals were housed in
normal conditions with 12-h light/dark cycle and water and food
available ad libitum. Animal handling and experimentation were
performed in accordance with the national regulation of the usage
and welfare of laboratory animals and approved by the Animal
Experiment Committee in State Provincial Office of Southern
Finland.
Treatment Trials
Lipopolysaccharide from Escherichia coli (clone 055:B5, Sigma-
Aldrich, St. Louis, MO, United States) was dissolved to 1 mg/ml
in sterile PBS and intraperitoneally administered to 4-month-old
mice at a dose of 1 mg/kg. Two hours after LPS administration,
mice were treated with 60 mg/kg CuII(atsm) dissolved in
SSV solution containing 0.9% (w/v) NaCl, 0.5% (w/v) sodium
carboxymethylcellulose, 0.5% (v/v) benzyl alcohol, and 0.4% (v/v)
Tween 80, or SSV alone by oral gavage. CuII(atsm) was prepared
according to published procedures (Gingras et al., 1962). 23.5 h
after LPS administration, mice were injected with MPIO-VCAM-
1 (conjugate) that was prepared according to Montagne et al.
(2012) by coating MyOne Tosyl Activated Dynabeads (Thermo
Fisher Scientific, Waltham, MA, United States) with 0.1 M
sodium borate buffer (pH 9.5) and conjugating with VCAM-1
antibody (40 µg/1 mg of beads, BD Biosciences, San Jose, CA,
United States) in 3 M ammonium sulfate at 37◦C for 48 h . The
conjugate was blocked with 0.5% (w/v) bovine serum albumin
(BSA) in PBS-Tween for 24 h at 37◦C and stored in 0.1% (w/v)
BSA in PBS-Tween at 4◦C. Each animal received an intravenous
dose of the MPIO-VCAM-1 conjugate containing 1.0 mg/kg of
Fe 30 min prior to imaging.
Imaging of Brain Inflammation in vivo
Magnetic resonance imaging was performed using a Biospec
9.4 T/12 cm system (Bruker, Germany) using a volume coil
transmit/surface coil receive pair (Rapid Biomed, Germany)
to produce 3D T2∗ weighted images (spatial resolution of
78 µm × 78 µm × 78 µm, TE/TR 12 ms/200 ms, flip angle
of 25◦, acquisition time 52 min). Four consecutive slices were
used to construct minimum intensity projections. Systematic
variation in signal intensity was removed prior to analysis by
normalization to overall brain signal intensity. This approach
allowed reliable detection of hypointense regions due to contrast
agent. Data are the mean percentages of VCAM-1 signal area
in nine consecutive minimum intensity projections per animal
relative to control, beginning from the first slice where the
hippocampus is visible. The VCAM-1 signal area was determined
in oval regions of interest encompassing the coronal brain section
within each image, and images were manually thresholded by a
blinded investigator.
Neonatal Astrocyte Cultures
For neonatal astrocyte-enriched cultures, newborn C57Bl/6J mice
were decapitated, and the brains removed and placed into ice-
cold preparation buffer (containing 68 mM NaCl, 2.7 mM KCl,
110 µM KH2PO4, 84.5 µM Na2HPO4, 29 mM sucrose, 2.8 mM
glucose, 20 U/mL penicillin, and 34.4 pM streptomycin). Brains
were sequentially passed through 250 and 135 µm gauze and
centrifuged at 500 × g for 5 min. Cell pellets were resuspended
in growth medium consisting of high glucose DMEM (Life
Technologies, Thermo Fischer Scientific) containing 10% (v/v)
FBS (Bovogen, VIC, Australia), 20 U/mL penicillin, and 34.4 pM
streptomycin (Life Technologies) and plated at a density of
150,000 cells/cm2. Cells were maintained at 37◦C with 10% CO2.
The growth medium was replaced every 7 days, and experiments
were performed after 14 DIV.
Adult Astrocyte Cultures
Astrocyte cultures were prepared as described previously (Pihlaja
et al., 2011) with some modifications. Briefly, cortices were
isolated from 6- to 8-week-old mice, the tissue suspended
in Hank’s Balanced Salt Solution (Lonza, Allendale, NJ,
United States) and centrifuged at 500 × g for 5 min. After
the addition of 0.25% trypsin-EDTA (Life Technologies, Great
Island, NY, United States), the suspension was incubated at 37◦C
for 30 min with occasional shaking. After the addition of fresh
culture medium to neutralize the effect of trypsin, the suspension
was centrifuged at 500 × g for 5 min. The cell suspension was
added on top of Percoll (Sigma) and centrifuged. The layer of glial
cells was washed once with fresh culture medium. The cells were
plated onto poly-L-lysine pre-coated flask in DMEM/F12 media
containing 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin–
streptomycin, and G5 supplement (Life Technologies, Great
Island, NY, United States). Microglia were removed by shaking
the plates before the experiments. Cells were used for experiments
at passages 4–8.
Primary Microglia
Microglia were harvested from astrocyte-enriched cultures plated
at 65,000 cells/cm2 in six-well plates or T175 flasks after 18
DIV. Adherent glial cells were washed in PBS and incubated at
37◦C with 1:5 dilution of 10× Trypsin-EDTA (Sigma-Aldrich)
in high glucose DMEM until astrocyte detachment was complete
(∼25 min). Astrocyte-conditioned media was added to adherent
microglia in 6 well plates. Microglia in T175 flasks were scraped,
counted and re-plated at a density of 65,000 cells/cm2. The
media was changed to IMDM phenol red free media (Life
Technologies) containing 10% (v/v) FBS, 20 U/mL penicillin, 34.4
pM streptomycin, and 2 mM L-glutamine (Life Technologies) the
following day and cells were allowed to rest for a further 2 days
prior to experiments.
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Cell Stimulation and Treatment
Cells were stimulated with 15 ng/ml IFNγ and 10 ng/ml TNFα
(Peprotech, Stockholm, Sweden), or 20 µg/ml LPS (Sigma-
Aldrich) for 24–48 h, as indicated. CuII(atsm) (10 mM), prepared
fresh in DMSO, was diluted in cell culture media and added
to cells at concentrations from 0.2 to 2 µM for the indicated
times. Minocycline (Sigma Aldrich) was used at 20 µM. Control
groups were treated with the vehicle solutions of the treatment
groups.
MTT Assay
Cell viability was determined using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Amresco
Inc., OH, United States). The MTT assay was performed by
addition of 0.5 mg/ml (final concentration) MTT to the cell
media. Cells were incubated at 37◦C until blue crystals were
visible by eye (approximately 30–60 min). The media was
removed and replaced with 100 µl of DMSO per well to
dissolve the crystals. One hundred microliter aliquots were
distributed to 96-well plate wells and the absorbance at 585 nm
was determined using an EnSpire R© Multimode Plate Reader
(Perkin Elmer, Waltham, MA, United States). MTT reduction
was blank corrected and expressed as a percentage of untreated
controls.
Lactate Dehydrogenase (LDH) Assay
Cell death was determined by measuring the enzymatic activity
of extracellular LDH released from cells due to loss of membrane
integrity indicating cell death using a Cytotoxicity Detection
Kit (Roche, Basel, Switzerland) according to the manufacturer’s
instructions. Briefly, media samples were combined with reaction
mixture and absorbance measured at 492 nm using an EnSpire R©
Multimode Plate Reader. Extracellular LDH activity was
expressed as percentage of total cellular LDH activity determined
from untreated cells lysed in culture media containing 1% triton
X-100.
Nitric Oxide (NO) Measurement
Nitric oxide concentrations in media were determined using a
Nitric Oxide Assay Kit (Abcam, England, United Kingdom) or
a Griess Reagent Kit (Thermo Fisher Scientific) according to
the manufacturer’s protocols. Briefly, standards were prepared
by serial dilution of the nitrite standard solution to final
concentrations between 0 and 30 µM. 100 or 240 µl,
for each respective kit, of freshly collected samples and
standards (in duplicate) in 96-well microplate (Greiner Bio-
One, Frickenhausen, Germany) were reacted with Griess
reagents 1 and 2 (50 or 30 µl of each reagent, for each
respective kit). Following 15 min of color development
at RT, absorbance at 540 nm was determined using an
EnSpire R© Multimode Plate Reader. Standard curves were
constructed, and sample nitrite concentrations were calculated
from standard curves. Results were expressed as percentage
NO released relative to TNFα- and IFNγ-stimulated positive
controls.
Quantitative Real-Time Polymerase
Chain Reaction
Total RNA was isolated from cells using the MagMaxTM Total
RNA isolation kit or from frozen tissue samples using TRIzol R©
(both from Invitrogen, Thermo Fisher Scientific), according
to the manufacturer’s instructions. RNA concentrations
were measured using the Qubit R© 2.0 fluorometer (Life
Technologies) or NanoDrop Spectrophotometer (Thermo
Fisher Scientific). RNA (200 ng–2 µg) was reverse transcribed
using random hexamers and High Capacity cDNA kit (Life
Technologies) or Maxima reverse transcriptase (Fermentas,
Thermo Fisher Scientific). The relative expression levels of
mRNA were measured according to the manufacturer’s protocol
by qRT-PCR (StepOnePlus; Life Technologies, LightCycler
480; Roche, Basel, Switzerland, or QuantStudio 6; Thermo
Fisher Scientific) using TaqMan chemistry and specific
assays-on-demand target mixes (Arg1 Mm00475988_m1,
Tgfb1 Mm01178820_m1, Ccl2 Mm00441242_m1, Tnf
Mm00443260_g1 or Mm00443258_m1, Mt1 Mm00496660_g1,
Il1a Mm00439620_m1, Il1b Mm00434228_m1, Il6
Mm00446190_m1, Nos2 Mm00440502_m1, Ptgs2
Mm00478374_m1; Life Technologies). The expression
levels were obtained by normalizing the target gene to the
geometric mean of GAPDH and beta-actin (Mm99999915_g1
and Mm02619580_g1, respectively; Life Technologies), and
presented as fold change in the expression using the 2−11Ct
method, where Ct is the threshold cycle value.
Enzyme-Linked Immunosorbent Assay
(ELISA)
Monocyte chemoattractant protein 1 (MCP-1/CCL2) and
interleukin 6 (IL-6) concentrations were quantified by ELISA
using the Mouse CCL2/JE/MCP-1 DuoSet and Mouse IL-6
DuoSet (R&D systems, Minneapolis, MN, United States),
respectively, according to the manufacturer’s instructions.
Results were expressed as percentages relative to the LPS or
TNF-α and IFNγ-stimulated positive controls.
Inductively Coupled Plasma Mass
Spectrometry (ICP-MS)
Inductively coupled plasma mass spectrometry analysis of metal
levels was performed as reported previously (Grubman et al.,
2014b). Briefly, cell pellets collected for metal analysis were
digested overnight in concentrated nitric acid (Aristar, BDH,
Kilsyth, VIC, Australia), after which samples were heated for
20 min at 90◦C. The volume of each sample was reduced to
approximately 40–50 µl then 1 ml of 1% (v/v) nitric acid diluent
was added to the samples. Some samples were analyzed using
laser ablation ICP-MS in micro-droplet format as described
previously (Yang et al., 2005; Hare et al., 2016). Briefly, cell
cultures and certified element copper standard (100014-1; Choice
Analytical, Australia) were prepared in phospho-safe extraction
buffer (Merck). One microliter of each sample was pipetted
onto a glass slide and left to air-dry overnight. Droplet residues
were ablated off the slide surface using laser ablation and
analysed using Iolite software (Paul et al., 2015; Hare et al., 2017).
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FIGURE 1 | Copper delivery reduces inflammation induced by administration of LPS. (A) Timeline demonstrating time points for administration of the indicated
compounds to adult mice and in vivo imaging of inflammation by MRI. (B) Representative MRI images acquired 30 min after intravenous administration of
MPIO-VCAM-1 (24 h after LPS and 22 h after CuII(atsm) or SSV) showing signal voids corresponding to MPIO binding. (C) Quantitative analysis of the volume of
signal void in the brain induced by MPIO-VCAM-1 following treatment with LPS and CuII(atsm). (D–F) Cultured adult astrocytes were stimulated with 20 µg/ml LPS
with or without 0.5 µM CuII(atsm) for 48 h and (D) MTT reduction, (E) IL-6 secretion, and (F) MCP-1 secretion were measured 48 h later. Sample sizes per group (n)
as indicated. ∗p < 0.05 compared to control, #p < 0.05 compared to LPS-treated group. ns, not significant. nd, not detected.
Measurements were made using an Agilent 7700x series ICP-
MS instrument or a NWR-213 laser ablation unit (Electro
Scientific Industries, Portland, OR, United States) hyphenated
to an Agilent 8800 ICP-QQQ-MS. The concentrations of copper
were calculated as µg of metal per mg of protein based on
the protein concentration of the sample, as determined by BCA
protein assay (Thermo Fisher Scientific).
X-ray Fluorescence Microscopy (XFM)
The distribution of copper was mapped at the XFM beamline
(Paterson et al., 2011) at the Australian Synchrotron on
cryofrozen freeze-dried cell culture samples grown on SiN X-ray
transparent membranes, as described previously (Grubman et al.,
2014a). An incident beam of 12.7 keV X-rays was used to induce
K-shell ionization of copper, while providing adequate separation
of the Rayleigh and Compton peaks from the elemental
fluorescence of interest. The incident beam was focused to a
∼1.5 µm spot (full-width at half maximum) using a Kirkpatrick–
Baez mirror pair and specimens were fly-scanned through X-ray
focus. The resulting XRF was collected in event mode using
the low latency, 384-channel Maia XRF detector (Ryan et al.,
2014) situated in the backscatter geometry. Full XRF spectra were
used to reconstruct copper maps of the specimen using a virtual
pixel size of 0.8 µm (corresponding to the sample interval),
giving a pixel transit time of 25 µs. Reference foils of Mn and
Pt (Micromatter, Canada), were scanned in the same geometry
at regular intervals throughout the measurement and used as
references to establish elemental quantitation. Deconvolution
of the Maia data was performed using GeoPIXE v6.6 software
(Kirkham et al., 2011).
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Statistics
Results were analyzed by ANOVA followed by Holm–Sidak’s
multiple comparison test using GraphPad Prism software.
Statistical significance was assumed if p< 0.05. Data presented in
graphs represent the experimental mean ± SEM of the indicated
number of independent experiments, each derived from multiple
technical replicates.
RESULTS
The Copper Complex CuII(atsm) Is
Anti-inflammatory in vivo
Peripheral inflammation induced by LPS triggers an
inflammatory response that is characterized by increased
expression of pro-inflammatory cytokines in the brain and
plasma (Thomson et al., 2014). Furthermore, brain expression
of VCAM-1, which plays a major role in the trafficking of
leukocytes across the blood–brain barrier, is upregulated in
response to systemic LPS (O’Sullivan et al., 2010; Thomson et al.,
2014). To study the effect of a copper bis(thiosemicarbazone)
complex on peripheral inflammation induced by systemic
LPS, we employed a sophisticated in vivo MRI approach
to measure brain inflammation that detects brain VCAM-1
expression in live animals. For this purpose, microsized particles
of iron oxide targeting VCAM-1 (MPIO-VCAM-1) were
intravenously administered to mice 30 min prior to imaging by
MRI (Figure 1A). The MRI imaging revealed a robust, close
to 100% increase in the expression of VCAM-1 at 24 h after
administration of 1 mg/kg LPS (Figures 1B,C).
To investigate whether the copper complex, CuII(atsm),
possesses anti-inflammatory activity in vivo, mice were treated
with a single dose of CuII(atsm) by oral gavage after peripheral
administration of LPS. As the inflammatory response in
brain peaks 1 h after administration of LPS (Qin et al.,
2007), mice were treated with CuII(atsm) 2 h after LPS
administration to investigate the effect of CuII(atsm) on
an ongoing inflammatory response. Mice were administered
60 mg/kg CuII(atsm) as we have demonstrated this to be
sufficient to induce neuroprotective effects in vivo (Huuskonen
et al., 2017). MPIO-VCAM-1 imaging revealed a significant,
∼20% reduction in the level of brain VCAM-1 expression in
the CuII(atsm)-treated mice compared to control, SSV-treated
mice at 24 h after LPS injection (Figure 1C). These data
demonstrate the efficacy of the neuroprotective agent CuII(atsm)
in reducing acute cerebrovascular inflammation (measured as
VCAM-1 expression) caused by systemic administration of LPS
in vivo.
CuII(atsm) Alleviates LPS-Induced
Inflammation in Primary Adult Astrocytes
Given that our in vivo findings during acute neuroinflammation
suggest that copper may regulate inflammatory pathways, we next
investigated inflammation in vitro utilizing adult astrocytes co-
stimulated with LPS and CuII(atsm) for 48 h. Neither 20 µg/ml
LPS or 0.5 µM CuII(atsm) alone or combined were toxic after
48 h (Figure 1D). This concentration of CuII(atsm) is consistent
with our previous pharmacokinetic studies which demonstrate
CuII(atsm) concentration reaches 0.6 µM in the mouse CNS
following a single administration of 30 mg/kg (Hung et al., 2012).
As expected, secretion of the cytokine IL-6 was strongly induced
by LPS treatment in adult astrocytes (Figure 1E). This was
significantly attenuated by co-treatment with CuII(atsm). MCP-1
(CCL-2) is a chemoattractant cytokine, the suppression of which
is known to be protective during neuroinflammation (Madrigal
and Caso, 2014). To assess the effects of copper delivery on
LPS-induced production of MCP-1, we next measured secreted
MCP-1 (Figure 1F). LPS treatment induced a ∼10-fold increase
in MCP-1 secretion from adult astrocytes, which was reduced by
co-treatment with CuII(atsm).
Although LPS is useful to investigate acute inflammatory
insults, and cultured cells robustly respond to it, LPS is unlikely
to directly stimulate brain cells in vivo due to poor blood–brain
barrier penetration (Banks and Robinson, 2010). Therefore, we
further studied the anti-inflammatory potential of CuII(atsm) in
cultured microglia and astrocytes stimulated with endogenous
mediators of inflammation.
CuII(atsm) Exerts Anti-inflammatory
Effects in Primary Microglia
Modulation of microglial activity is a viable therapeutic approach
for diseases with a strong neuroinflammatory component. To
determine whether copper bis(thiosemicarbazone) complexes
modulate the inflammatory phenotype of microglia, we used a
treatment paradigm where primary microglia were stimulated
with the pro-inflammatory cytokines IFNγ and TNFα during
co-treatment with CuII(atsm). The maximum non-toxic doses
of CuII(atsm) for cultured microglia based on MTT and LDH
assays were chosen for these experiments (Supplementary
Figure S1). The inflammation-modulating activity of CuII(atsm)
was also compared to that of the well-known anti-inflammatory
agent, minocycline (Malm et al., 2010). We first tested the
effects of non-toxic concentrations (Figure 2A) of CuII(atsm)
on IFNγ/TNFα-induced NO production. The amount of NO
was increased 2.5-fold after the 48 h IFNγ/TNFα stimulation
(Figure 2B). Co-treatment with 0.5 µM CuII(atsm) significantly
suppressed the IFNγ/TNFα-induced NO production by ∼50%,
whereas CuII(atsm) alone did not affect NO secretion.
We next measured secreted MCP-1 (Figure 2C) and the
mRNA levels of the MCP-1 gene, Ccl2, (Figure 2D) in primary
microglial cultures. As expected, treatment with IFNγ/TNFα
increased the secretion of MCP-1 into the media and the mRNA
level of Ccl2. When compared to IFNγ/TNFα stimulation, co-
treatment with CuII(atsm) reduced the MCP-1 protein secreted
into the media by 40% (Figure 2C). This reduction was
comparable to that conferred by minocycline (Figure 2C).
Similarily, CuII(atsm) treatment was effective at reducing the
mRNA expression of Ccl2 (Figure 2D). Co-treatment with
CuII(atsm) also reduced the mRNA expression of Tnf encoding
TNFα (Figure 2E).
Further analysis of inflammatory gene expression revealed
these effects of CuII(atsm) to be quite selective. In contrast to Ccl2
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FIGURE 2 | Copper delivery dampens microglial activation during inflammation. Primary microglia were stimulated with 15 ng/ml IFNγ and 10 ng/ml TNFα with or
without 0.5 µM CuII(atsm). (A) MTT reduction was measured to determine the cell viability 24 h later. Primary microglia were stimulated with 15 ng/ml IFNγ and
10 ng/ml TNFα with or without 0.5 µM CuII(atsm) or 20 µM minocycline for 24 h. (B) Nitric oxide release into the media was measured 24 h later. (C) The secretion
of MCP-1 into the media was measured by ELISA. qRT-PCR was used to measure microglial mRNA expression levels of (D) Ccl2, (E) Tnf, and (F) the indicated
genes. (F) Presented as log fold-increase over control. Sample sizes per group (n) as indicated. ∗p < 0.05 compared to control, #p < 0.05 compared to
IFNγ/TNFα-treated group. ns, not significant.
and Tnf, CuII(atsm) did not significantly alter the expression of
Il1a, Il1b, Il6, Ptgs2, or Nos2 (Figure 2F). The latter is intruiging,
as this gene codes for inducible NO synthase, and would be
expected to be decreased by CuII(atsm) in light of the attenuated
NO levels (Figure 2B). As expected, IFNγ/TNFα significantly
decreased expression of two anti-inflammatory genes, Tgfb1 and
Arg1 (Figure 2F). While CuII(atsm) did not alter this response,
minocycline increased expression of Tgfb1 and further decreased
expression of Arg1.
CuII(atsm) Dampens the Activation of
Primary Astrocytes During Inflammation
To determine whether the observed anti-inflammatory effects
of copper delivery were specific for microglia only, we next
employed a similar treatment paradigm for murine astrocytes
with non-toxic concentrations (Figures 3A,B). In comparison
to neonatal astrocytes stimulated with IFNγ/TNFα, co-
treatment with CuII(atsm) resulted in significantly reduced
secretion of MCP-1 (Figure 3C) and NO (Figure 3D) into
the culture media. This was accompanied by a corresponding
attenuation of IFNγ/TNFα-induced Ccl2 (Figure 3E), Nos2
(Figure 3F), and Tnf (Figure 3G) expression by CuII(atsm).
Analysis of other inflammatory genes revealed IFNγ/TNFα
increased expression of Tgfb1 and Arg1 in astrocytes,
which was either attenuated or exacerbated by CuII(atsm)
co-treatment, respectively (Figure 3H). IFNγ/TNFα treatment
increased expression of Il1a, Il1b, and Il6, but not Ptgs2
(Figure 3H). Co-treatment with CuII(atsm) did not diminish
expression of these genes, and actually increased expression of
Il1a.
CuII(atsm) Delivers Bioavailable Copper
Into Cells
Metal accumulation in response to treatment with CuII(atsm)
was examined to determine the effect of the compound on metal
delivery in primary microglia and neonatal astrocytes under basal
and inflammatory conditions. Treatment of either astrocytes
or microglia with CuII(atsm) caused a significant increase in
cellular copper levels as measured by ICP-MS (Figures 4A,C).
IFNγ/TNFα alone did neither alter copper levels as compared
to basal levels nor alter copper content when co-treated with
CuII(atsm) relative to CuII(atsm) alone.
Metallothionein-1 is a critical metal-binding protein that
is involved in the regulation of metals and the modulation
of anti-inflammatory and anti-oxidative pathways (Huh et al.,
2007). To determine whether MT1 is associated with the anti-
inflammatory effects induced by copper delivery, Mt1 expression
was investigated. In contrast to reports indicating that Mt1
expression is increased by pro-inflammatory conditions (De
et al., 1990; Manso et al., 2011; Everhardt Queen et al., 2016),
here Mt1 expression was decreased when either astrocytes or
microglia were treated with IFNγ/TNFα alone (Figure 4B;
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FIGURE 3 | Anti-inflammatory effects of copper delivery in astrocytes. Neonatal astrocytes were stimulated for 48 h with 15 ng/ml IFNγ and 10 ng/ml TNFα with or
without 2µM CuII(atsm) for the final 24 h (A–H). (A) MTT reduction and (B) LDH release was measured to determine the cell viability and cell death, respectively, after
treatment. (C) MCP-1 secretion and (D) nitric oxide release were measured after treatment. qRT-PCR was used to measure astrocyte mRNA expression levels of
(E) Ccl2, (F) Nos2, (G) Tnf, and (H) the indicated genes. (H) Presented as log fold-increase over control. Sample sizes per group (n) as indicated, or 6–7/treatment
group for (H). ∗p < 0.05 compared to control, #p < 0.05 compared to IFNγ/TNFα-treated group. ns, not significant.
Supplementary Figure S2). Treatment of astrocytes or microglia
with CuII(atsm) increased Mt1 expression (Figures 4B,D). This
expression was unchanged by co-treatment with IFNγ/TNFα
As Mt1 expression is well known to be strongly regulated by
copper levels via metal regulatory transcription factor 1 (Juarez-
Rebollar et al., 2017), these results indicate that CuII(atsm) is
delivering bioavailable copper into cultured glial cells. That the
presence or absence of IFNγ/TNFα did not alter CuII(atsm)-
mediated copper content or Mt1 expression of either astrocytes
or microglia indicates that inflammatory conditions do not alter
the accumulation of copper by glial cells, at least in culture.
Finally, XFM was used next to investigate the delivery
and subcellular localisation of copper into primary microglia.
Inelastic scatter (Compton) of incident photons was used to
define the boundaries of cells in order to quantify metal levels for
each individual cell (Figure 4E). We observed a dramatic increase
in cellular copper in response to IFNγ/TNFα plus CuII(atsm)
treatment, with little overlap in copper content per cell as
compared to cells treated in absence of CuII(atsm) (Figure 4F).
Copper appears to be diffusely localized throughout microglia,
with no discernable nuclear exclusion or punctate localisation.
In microglia treated with CuII(atsm), copper levels per cell are
somewhat heterogeneous, with some cells accumulating much
more copper than others. Together, these results demonstrate
that CuII(atsm) efficiently delivers copper into cells under both
basal and inflammatory conditions.
DISCUSSION
Modulation of copper and inflammation are both beneficial
during neurodegeneration (Soon et al., 2011; Hung et al., 2012;
Heneka et al., 2013; Roberts et al., 2014; Spangenberg and
Green, 2016), yet the direct inflammation-modulating effects of
copper compounds have remained relatively unexplored. Here
we demonstrate, for the first time, that a bis(thiosemicarbazone)
copper complex has anti-inflammatory effects in cultured
microglia and astrocytes, and moderates inflammation in mice
subjected to acute peripheral inflammation.
The role of copper in neuroinflammatory conditions,
including AD, is not clear. Multiple studies have shown that
increases in free copper levels impairs the clearance of Aβ
and worsens behavioral outcome in animal models of AD
(Kitazawa et al., 2009; Singh et al., 2013; Kitazawa et al.,
2016). Copper triggers activation of cultured microglia, causing
them to release the pro-inflammatory cytokine TNFα and NO
into the culture media (Hu et al., 2014; Yu et al., 2015).
Accordingly, sequestering systemic copper via D-penicillamine
or tetrathiomolybdate reduces systemic oxidative stress in AD
patients (Squitti et al., 2002), and inhibits acute LPS-induced
peripheral inflammatory reactions in vivo (Wei et al., 2011).
However, these chelator studies did not assess inflammation
in the brain, where in contrast, intracellular copper deficiency
elicits a neurodegenerative phenotype in mice and promotes the
activation of microglia (Zucconi et al., 2007). Together, these
studies suggest that too much or too little copper is detrimental
and that intracellular, physiological copper concentrations are
essential for the prevention of neuroinflammation. In line
with this, neuroinflammatory conditions, including AD, have
profoundly disturbed copper homeostasis. Copper-induced Aβ
deposition occurs concomitantly with a reduction in the
amount of intracellular, bioavailable copper, rendering the
AD brain copper deficient (Schrag et al., 2011; Choo et al.,
2013). In contrast to the inflammatory effects of free copper
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FIGURE 4 | CuII(atsm) delivers copper into cells. (A,B) Neonatal astrocytes were treated for 48 h with 15 ng/ml IFNγ and 10 ng/ml TNFα with or without 2 µM
CuII(atsm) for the final 24 h. (C,D) Microglia were treated for 24 h and with 15 ng/ml IFNγ and 10 ng/ml TNFα with or without 0.5 µM CuII(atsm). Cellular copper
content of (A) astrocytes and (C) microglia was measured by ICP-MS. mRNA expression of Mt1 was measured by qRT-PCR in (B) astrocytes and (D) microglia.
Sample sizes per group (n) as indicated. (E) Representative images of microglia analyzed for cellular copper content by XFM (reflected by elemental areal density).
Scale bar 100 µm. (F) Quantification of XFM-determined copper levels per cell in microglia treated with 15 ng/ml IFNγ and 10 ng/ml TNFα with or without 0.5 µM
CuII(atsm). Cells per treatment group (n) as indicated. ∗p < 0.05 compared to control, #p < 0.05 compared to IFNγ/TNFα-treated group.
treatments, we find that the copper bis(thiosemicarbazone)
complex applied in the current study moderates peripherally
induced neuroinflammation in vivo and attenuates inflammation
in cultured glial cells. This is in line with our previous findings
that modulation of copper by cell permeable copper-delivering
compounds is potently neuroprotective in various in vivo
models of neurodegeneration (Crouch et al., 2009; Adlard
et al., 2011; Soon et al., 2011; Hung et al., 2012; McAllum
et al., 2013; Roberts et al., 2014), and that these protective
effects are accompanied by modulation of acute and chronic
neuroinflammation in vivo (Soon et al., 2011; Roberts et al.,
2014; Huuskonen et al., 2017). The discrepancy between free
copper and these complexes is likely due to the specific actions
of these copper complexes, redistributing copper ions, and
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circumventing the endogenous copper trafficking machinery to
restore copper homeostasis. The strong neuroprotective effects
of these complexes demonstrates the potential therapeutic utility
of our approach: CuII(atsm) is currently under investigation in
clinical trials for the treatment of PD and ALS (NCT02870634,
NCT03136809, and NCT03204929).
We demonstrated by MRI imaging that an acute inflammatory
insult induces a robust cerebrovascular inflammatory phenotype,
which is dampened by treatment with CuII(atsm). Our findings
corroborate earlier reports whereby the expression of VCAM-
1 in the brain is upregulated in response to systemic LPS
(O’Sullivan et al., 2010; Thomson et al., 2014). VCAM-1 is
an adhesion molecule overexpressed by the activated cerebral
vasculature during inflammation and is considered a promising
marker for molecular imaging of neuroinflammation in CNS
disorders (Gauberti et al., 2014). For the first time, we report that
peripheral LPS-induced brain VCAM-1 expression is modulated
by a copper complex. It has been shown that superoxide
dismutase 1 (SOD1/Cu-Zn SOD) plays an important role in
scavenging the superoxide anions generated by inflammatory
challenge and limiting VCAM-1-mediated propagation of the
injury (Ishigami et al., 2011). Since CuII(atsm) is known to
increase SOD1 copper content in animal models of ALS (Roberts
et al., 2014), we hypothesize that the antioxidant reactions raised
by CuII(atsm) may contribute to reducing VCAM-1 expression
after systemic LPS challenge. Interestingly, administration of
copper-bound anti-inflammatory agents significantly reduces
endothelial expression of VCAM-1 after acute injury in rabbits
(Puranik et al., 2016). By contrast, an in vitro study has shown
that treatment of human aortic endothelial cells with cupric
sulfate increases VCAM-1 expression, indicative of increased
inflammation (Wei et al., 2014). These apparently conflicting
results can be reconciled by the fact that the latter study did
not assess the effect of copper under inflammatory conditions,
used supra-physiological concentrations of copper, and used free
copper as opposed to a membrane-permeable copper delivery
agent, which as discussed above does not allow for tight control
of metal delivery, or a direct comparison to be made to our
data. While examination of the attenuation of inflammation by
CuII(atsm) in vivo in the current study is limited to VCAM-
1 expression, our previous studies demonstrate that CuII(atsm)
robustly attenuates the neuroinflammation associated with acute
and chronic neurodegenerative insults (Soon et al., 2011; Roberts
et al., 2014; Huuskonen et al., 2017). Nevertheless, future studies
will be useful to examine additional markers of inflammation
both in the CNS and periphery to further elucidate the effects of
CuII(atsm) in acute models of inflammation.
Inflammation in the CNS is regulated by microglia and to
a lesser extent astrocytes. Our in vitro data support the notion
that copper delivery is beneficial in these glial cells through the
demonstration that under inflammatory conditions, treatment
with CuII(atsm) reduced secretion of NO and IL-6, reduced the
expression of the gene encoding the classical pro-inflammatory
molecule TNFα, and reduced both the expression of the gene
encoding MCP-1 and the secretion of the protein into the culture
media. However, no changes were observed in the expression
of several other inflammatory genes. This may indicate that the
anti-inflammatory effects of CuII(atsm) are somewhat selective.
Interestingly, NO secretion by microglia is attenuated by
CuII(atsm), but not the elevated expression of Nos2. This suggests
post-transcriptional modifications are responsible for decreased
NO secretion. Indeed, a direct interact of copper with NO
species has been reported for microglia (Rossi-George and Guo,
2016). Such interactions could also influence other inflammatory
mediators, and this remains to be determined. An alternative
option for lack of change in expression is that more wide-ranging
anti-inflammatory effects were not able to be observed under the
conditions utilized in this study but may occur under different
conditions. In support of this, minocycline has been reported to
attenuate the expression of many inflammatory genes, however
several were examined here and were found to be unaltered
by minocycline treatment, including Nos2, Il6, Il1b, and Ptgs2
(Matsui et al., 2010; Piotrowska et al., 2017). That CuII(atsm)
consistently induced more robust anti-inflammatory effects than
minocycline supports the strong anti-inflammatory action of
CuII(atsm).
Arginase-1 and TGB-β are strongly induced in microglia and
macrophages during anti-inflammatory conditions and are often
used as a marker of anti-inflammatory/alternatively activated
cells (Jha et al., 2016). However, mounting evidence suggests
that this bipolar classification of microglia is not reflective of
the complexity of dynamic microglial transcriptional fingerprints
in the physiological and pathological brain (Ransohoff, 2016;
Keren-Shaul et al., 2017). Our results are consistent with this,
with microglia exhibiting decreased expression of both Arg1
and Tgfb1 in response to IFNγ/TNFα-induced inflammation,
whereas both are increased in response to the same stimuli in
cultured astrocytes. It is important to note that our astrocyte
cultures contain a substantial subpopulation of microglia.
The phenotype of both microglia and astrocytes are strongly
influenced by communication with neighboring cells. For
example, MCP-1 released by astrocytes is known to activate
microglia, cause their pro-inflammatory phenotype switch, and
to enhance their migratory ability (He et al., 2016), and the
presence of even a small number of microglia is capable
of altering the phenotype of cultured astrocytes (Liddelow
et al., 2017). Given this extensive crosstalk between microglia
and astrocytes, this mixed glial culture perhaps represents
a more physiological model than either isolated microglia
or astrocytes. Regardless, with the exception of Arg1 and
Tgfb1, that similar anti-inflammatory results were obtained
in both cultured astrocytes and microglia further strengthens
the validity of these effects and the likelihood of translation
in vivo.
How does CuII(atsm) trigger the anti-inflammatory effects
demonstrated herein? CuII(atsm) can deliver bioavailable
copper into the CNS (Crouch et al., 2009; Roberts et al.,
2014). Conditions consistent with oxidative stress promote the
dissociation of copper from CuII(atsm) (Sirois et al., 2018).
This produces a targeted effect proven to be beneficial in
animal models of conditions such as stroke and ALS, where
neuroinflammation is strongly related to increased oxidative
stress (Roberts et al., 2014; Huuskonen et al., 2017). Copper-
induced increases in microglial and astrocytic Mt1 expression
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have been reported by others (Agullo et al., 1998; Bulcke and
Dringen, 2015) and are now confirmed by the current report.
This increase indicates copper dissociation from CuII(atsm).
In addition to the previously reported mechanisms of action
of CuII(atsm) connected to increased antioxidant scavenging
(Soon et al., 2011; Hung et al., 2012; Roberts et al., 2014), we
show here that MT1 may also mediate the protective effects of
CuII(atsm). Existing reports demonstrate that metallothioneins,
metal-buffering proteins with numerous protective functions,
modulate anti-inflammatory pathways (Inoue et al., 2009).
Mt1 expression is also upregulated in ALS patients and model
mice (Sillevis Smitt et al., 1994), in AD patients and in mice
modeling the disease, specifically in cells surrounding amyloid
plaques (Carrasco et al., 2006; Kim et al., 2012) and in astrocytes
(Kim et al., 2012). In vitro studies have demonstrated that in
addition to preventing amyloid neurotoxicity directly, MT1 also
suppresses Aβ-dependent microglial activation and reduces the
neurotoxicity of Aβ-stimulated microglia (Kim et al., 2012).
Furthermore, in vivo studies have reported that over-expression
of MT1 modulates key phenotypes of AD model mice in a
gender- and age-related manner (Kim et al., 2012), and extends
lifespan of ALS model mice (Tokuda et al., 2014). These studies
demonstrate the critical role of MT1 during neuroinflammatory
conditions, which may be involved in the therapeutic action
of CuII(atsm). While the in vitro results suggest inflammation
does not alter CuII(atsm) or copper accumulation, our previous
studies indicate the accumulation of copper from CuII(atsm)
is enhanced under disease conditions (Donnelly et al., 2012;
Roberts et al., 2014). Hence, it remains to be determined whether
the pharmacokinetics of CuII(atsm) in vivo are altered under
acute inflammatory conditions.
To have clinical utility, anti-inflammatory therapeutics must
be able to inhibit ongoing inflammation. For the in vivo analyses
in the current study, as 1 h is reportedly sufficient for LPS
to generate a robust inflammatory response (Qin et al., 2007),
the effects of CuII(atsm) administered 2 h after LPS are likely
to indicate the attenuation of ongoing inflammation, rather
than preventing the onset of inflammation. Similarly, while
inflammation was induced in microglia simultaneously with
CuII(atsm) treatment, primary astrocytes were treated both
simultaneously and 24 h following induction of inflammation.
Both paradigms elicited similar results demonstrating CuII(atsm)
attenuates prevailing inflammation in vitro. Furthermore, our
previous studies in animal models of several neurodegenerative
conditions also demonstrate that CuII(atsm) elicits robust
protective effects even when administered post-symptom onset
(Hung et al., 2012; McAllum et al., 2013; Huuskonen et al., 2017).
Thus CuII(atsm) can ameliorate ongoing inflammation.
CONCLUSION
Available treatment options for neuroinflammatory diseases are
inadequate and those available have limited efficacy. Discovering
novel approaches that modulate neuroinflammation are therefore
of immense therapeutic interest for these disorders. Here, we
demonstrated robust inflammation-reducing effects of a cell
permeable copper complex in both in vivo and in vitro models
of neuroinflammation. Given our newly reported insights into its
neuroimmune role, this study demonstrates that copper delivery
is a strong candidate for the development of therapies for
neuroinflammatory conditions.
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FIGURE S1 | Toxicity analysis of CuII(atsm) in primary microglial cultures. Primary
microglia were treated with the indicated concentrations of CuII(atsm) for 24 h.
(A) MTT reduction and (B) LDH release were measured after 24 h. N = 2–5/group.
∗p < 0.05 compared to control.
FIGURE S2 | Inflammation decreases metallothionein-1 expression in microglia.
Microglia were treated for 24 h with or without 15 ng/ml IFNγ and 10 ng/ml TNFα.
mRNA expression of Mt1 was measured by qRT-PCR. N = 7/group. ∗p < 0.05
compared to control.
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